STOCK TITAN
  1. Home
  2. News
  3. LLY

Lilly(Eli) & Co - LLY STOCK NEWS

Welcome to our dedicated news page for Lilly(Eli) & Co (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly(Eli) & Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lilly(Eli) & Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lilly(Eli) & Co's position in the market.

News
FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) has received FDA approval for Zepbound™ (tirzepatide) injection, the first obesity treatment activating GIP and GLP-1 hormone receptors. In clinical trials, adults lost an average of 48 lb. at the highest dose, with 1 in 3 patients losing over 58 lb. The drug is indicated for adults with obesity or those who are overweight with weight-related medical problems, promising hope for better weight management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
fda approval
-
News
OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders
Rhea-AI Summary
OrsoBio, a clinical-stage biopharmaceutical company, completed a $60 million Series A financing, bringing the total capital raised to $97 million. The funding will support the development of its innovative portfolio of four programs focused on obesity and associated metabolic disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
-
News
Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting
Rhea-AI Summary
Eli Lilly and Company will present updated data from studies of pirtobrutinib, a non-covalent Bruton's tyrosine kinase (BTK) inhibitor, at the 65th American Society of Hematology (ASH) Annual Meeting. The presentations will include safety and efficacy data for pirtobrutinib in multiple B-cell malignancies, such as mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.66%
Tags
none
News
Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) reported a 37% increase in revenue in Q3 2023, driven by growth from Mounjaro, Verzenio, and Jardiance. The company also earned $1.42 billion from the sale of rights for the olanzapine portfolio. Excluding revenue from the olanzapine portfolio and COVID-19 antibodies, revenue increased by 24%. Q3 2023 EPS was a loss of $0.06 on a reported basis and income of $0.10 on a non-GAAP basis. The company lowered its 2023 reported EPS guidance to $5.95 to $6.15 and non-GAAP EPS guidance to $6.50 to $6.70.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.66%
Tags
earnings
-
News
Hip-Hop Classic "It Takes Two" Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease
Rhea-AI Summary
Boehringer Ingelheim and Lilly have launched It Takes 2™, a health initiative to raise awareness about kidney disease and the benefits of complete testing. Clinical guidelines recommend using two tests, estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR), to detect kidney disease. More than 35 million adults in the U.S. have chronic kidney disease, but 90% are unaware of their condition. The initiative is targeted towards individuals with type 2 diabetes or high blood pressure who are at greater risk for kidney disease. Hip-hop artist Rob Base has reimagined his hit song 'It Takes Two' as 'It Takes 2 - The Remix' to support the initiative.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
none
-
News
Lilly Declares Fourth-Quarter 2023 Dividend
Rhea-AI Summary
Eli Lilly and Company announces a dividend of $1.13 per share for the fourth quarter of 2023, payable on Dec. 8, 2023, to shareholders of record on Nov. 15, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
dividends
News
FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis
Rhea-AI Summary
Eli Lilly's Omvoh receives FDA approval for the treatment of ulcerative colitis, achieving primary and secondary endpoints in clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
fda approval
-
News
Lilly to Participate in UBS Biopharma Conference 2023
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) will attend the UBS Biopharma Conference on Nov. 8, 2023. Patrik Jonsson, executive vice president; president, Lilly Immunology; president, Lilly USA; and chief customer officer, will participate in a fireside chat at 3 p.m., Eastern time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
conferences
-
News
Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 2023
Rhea-AI Summary
Eli Lilly and Company announces positive results from Phase 3 studies of Retevmo in lung cancer and thyroid cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement
Rhea-AI Summary
Eli Lilly and Company to announce Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
earnings
Stock LLY logo
Lilly(Eli) & Co

NYSE:LLY

LLY Rankings

#9 Ranked by Market Cap
#348 Ranked by Stock Gains
#1940 Ranked by Dividends

LLY Stock Data

714.63B
897.86M
0.16%
84.31%
0.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Indianapolis

About LLY

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.